ARID1A Maintains Differentiation of Pancreatic Ductal Cells and Inhibits Development of Pancreatic Ductal Adenocarcinoma in Mice

被引:58
|
作者
Kimura, Yoshito [1 ]
Fukuda, Akihisa [1 ]
Ogawa, Satoshi [1 ]
Maruno, Takahisa [1 ]
Takada, Yutaka [1 ]
Tsuda, Motoyuki [1 ]
Hiramatsu, Yukiko [1 ]
Araki, Osamu [1 ]
Nagao, Munemasa [1 ]
Yoshikawa, Takaaki [1 ]
Ikuta, Kozo [1 ]
Yoshioka, Takuto [1 ]
Wang, Zong [2 ]
Akiyama, Haruhiko [3 ]
Wright, Christopher V. [4 ,5 ]
Takaori, Kyoichi [6 ]
Uemoto, Shinji [6 ]
Chiba, Tsutomu [1 ]
Seno, Hiroshi [1 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Kyoto, Japan
[2] Univ Michigan, Cardiovasc Res Ctr, Dept Cardiac Surg, Ann Arbor, MI 48109 USA
[3] Gifu Univ, Dept Orthopaed, Gifu, Japan
[4] Vanderbilt Univ, Sch Med, Program Dev Biol, Nashville, TN 37212 USA
[5] Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37212 USA
[6] Kyoto Univ, Grad Sch Med, Dept Surg, Div Hepatobiliary Pancreat Surg & Transplantat, Kyoto, Japan
基金
日本学术振兴会; 美国国家卫生研究院;
关键词
Oncogene; Pancreatic Cancer; Transcriptional Regulator; Tumorigenesis; PAPILLARY-MUCINOUS NEOPLASMS; CANCER; MUTATIONS; INACTIVATION; EXPRESSION; COMPONENT; PROMOTES; PATHWAY;
D O I
10.1053/j.gastro.2018.03.039
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: The ARID1A gene encodes a protein that is part of the large adenosine triphosphate (ATP)-dependent chromatin remodeling complex SWI/SNF and is frequently mutated in human pancreatic ductal adenocarcinomas (PDACs). We investigated the functions of ARID1A during formation of PDACs in mice. METHODS: We performed studies with Ptf1a-Cre; Kras(G12D) mice, which express activated Kras in the pancreas and develop pancreatic intraepithelial neoplasias (PanINs), as well as those with disruption of Aird1a (Ptf1a-Cre; Kras(G12D); Arid1a(f/f) mice) or disruption of Brg1 (encodes a catalytic ATPase of the SWI/SNF complex) (Ptf1a-Cre; Kras(G12D); Brg1(f/f) mice). Pancreatic ductal cells (PDCs) were isolated from Arid1a(f/f) mice and from Arid1a(f/f); SOX9OE mice, which overexpress human SOX9 upon infection with an adenovirus-expressing Cre recombinase. Pancreatic tissues were collected from all mice and analyzed by histology and immunohistochemistry; cells were isolated and grown in 2-dimensional and 3-dimensional cultures. We performed microarray analyses to compare gene expression patterns in intraductal papillary mucinous neoplasms (IPMNs) from the different strains of mice. We obtained 58 samples of IPMNs and 44 samples of PDACs from patients who underwent pancreatectomy in Japan and analyzed them by immunohistochemistry. RESULTS: Ptf1a-Cre; Kras(G12D) mice developed PanINs, whereas Ptf1a-Cre; Kras(G12D); Arid1a(f/f) mice developed IPMNs and PDACs; IPMNs originated from PDCs. ARID1A-deficient IPMNs did not express SOX9. ARID1A-deficient PDCs had reduced expression of SOX9 and dedifferentiated in culture. Overexpression of SOX9 in these cells allowed them to differentiate and prevented dilation of ducts. Among mice with pancreatic expression of activated Kras, those with disruption of Arid1a developed fewer PDACs from IPMNs than mice with disruption of Brg1. ARID1A-deficient IPMNs had reduced activity of the mTOR pathway. Human IPMN and PDAC specimens had reduced levels of ARID1A, SOX9, and phosphorylated S6 (a marker of mTOR pathway activation). Levels of ARID1A correlated with levels of SOX9 and phosphorylated S6. CONCLUSIONS: ARID1A regulates expression of SOX9, activation of the mTOR pathway, and differentiation of PDCs. ARID1A inhibits formation of PDACs from IPMNs in mice with pancreatic expression of activated KRAS and is down-regulated in IPMN and PDAC tissues from patients.
引用
收藏
页码:194 / +
页数:18
相关论文
共 50 条
  • [1] Loss of ARID1A Expression Correlates With Tumor Differentiation and Tumor Progression Stage in Pancreatic Ductal Adenocarcinoma
    Zhang, Li
    Wang, Cuiping
    Yu, Shuangni
    Jia, Congwei
    Yan, Jie
    Lu, Zhaohui
    Chen, Jie
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2018, 17
  • [2] Pancreatic ductal adenocarcinoma and acinar cells: a matter of differentiation and development?
    Rooman, Ilse
    Real, Francisco X.
    GUT, 2012, 61 (03) : 449 - 458
  • [3] ARID1A Immunohistochemistry Loss in Intra-and Extrahepatic Cholangiocarcinomas and Comparison with Pancreatic Ductal Adenocarcinoma
    Gosse, Matthew
    Bellizzi, Andrew
    LABORATORY INVESTIGATION, 2025, 105 (03)
  • [4] Epigenetic regulator ARID1A and stem cell transcription factor SOX9 in the maintenance of pancreatic ductal cell differentiation state and development of intraductal papillary mucinous neoplasia (IPMN) and pancreatic ductal adenocarcinoma (PDAC)
    Cui, Naipeng
    Zhang, Jinsong
    Huang, Huatian
    Lu, Lingeng
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S748 - S751
  • [5] The acinar differentiation determinant PTF1A inhibits initiation of pancreatic ductal adenocarcinoma
    Krah, Nathan M.
    De La O, Jean-Paul
    Swift, Galvin H.
    Hoang, Chinh Q.
    Willet, Spencer G.
    Pan, Fong Chen
    Cash, Gabriela M.
    Bronner, Mary P.
    Wright, Christopher V. E.
    MacDonald, Raymond J.
    Murtaugh, L. Charles
    ELIFE, 2015, 4
  • [6] Inflammation and development of pancreatic ductal adenocarcinoma
    Shi, Juanjuan
    Xue, Jing
    CHINESE CLINICAL ONCOLOGY, 2019, 8 (02)
  • [7] Mast cells in pancreatic ductal adenocarcinoma
    Chang, David Z.
    ONCOIMMUNOLOGY, 2012, 1 (05): : 754 - 755
  • [8] Nardilysin inhibits pancreatitis and suppresses pancreatic ductal adenocarcinoma initiation in mice
    Ikuta, Kozo
    Fukuda, Akihisa
    Ogawa, Satoshi
    Masuo, Kenji
    Goto, Norihiro
    Hiramatsu, Yukiko
    Tsuda, Motoyuki
    Kimura, Yoshito
    Matsumoto, Yoshihide
    Kimura, Yuto
    Maruno, Takahisa
    Kanda, Keitaro
    Nishi, Kiyoto
    Takaori, Kyoichi
    Uemoto, Shinji
    Takaishi, Shigeo
    Chiba, Tsutomu
    Nishi, Eiichiro
    Seno, Hiroshi
    GUT, 2019, 68 (05) : 882 - 892
  • [9] Pancreatic ductal adenocarcinoma
    Gallmeier, E.
    Gress, T. M.
    INTERNIST, 2018, 59 (08): : 805 - 822
  • [10] Pancreatic Ductal Adenocarcinoma
    Heinemann, V.
    Schmidberger, H.
    ONKOLOGE, 2019, 25 (08): : 642 - 644